A pilot pharmacokinetic study of VAL413 in patients with recurrent pediatric solid tumors

Patients aged 2-30 with recurrent pediatric solid tumors including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma may be eligible for this trial

Further details of the trial can be found on clinicaltrials.gov (NCT04337177)

Submit an inquiry to our clinical team